Rocket Pharmaceuticals details advancing cardiovascular programs and RP-A501 pediatric update

Rocket Pharmaceuticals says three cardiovascular gene-therapy programs are advancing and that Phase 2 RP-A501 interim data show good tolerability with early pediatric efficacy signals; the company says cash runway extends into 2028, and Needham upgraded the stock to Buy.